May 21, 2025
PCI BIotech: Disclosure of voting rights for Chair of the Board
Oslo, 20 May 2025. PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) issue this notification on behalf of Hans…
Pharmaceuticals, Biotechnology and Life Sciences
Oslo, 20 May 2025. PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) issue this notification on behalf of Hans…
REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics…
Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in…
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult…
Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in…
Topline results for AP02 (inhaled nintedanib) confirmed safety and tolerability with limited systemic exposure and substantially improved lung exposure compared…
Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL…
Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical StudiesZURICH, May 20, 2025 (GLOBE…
BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…
Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports…